TREATMENT OF EXUDATIVE CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: Efficacy of Fractionated Proton Therapy (20 Gray Relative Biological Effectiveness in 8 Fractions).


Journal

Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 19 12 2017
medline: 25 4 2020
entrez: 19 12 2017
Statut: ppublish

Résumé

To evaluate treatment of circumscribed choroidal hemangioma by hyperfractionated proton beam therapy protocol (20 gray relative biological effectiveness in 8 fractions) on tumor control, attachment of retina and visual function. Retrospective review of patients treated between January 2010 and April 2015 with at least 6 months of follow-up. Forty-three patients with exudative and symptomatic circumscribed choroidal hemangioma were included. Before treatment, 41 (95%) presented an exudative retinal detachment, median visual acuity was 20/63 and median tumor thickness was 3.3 mm. Mean follow-up was 26 months (7-62). At last follow-up, all patients presented regression of ultrasound tumor thickness and 23/43 (53.5%) a totally flat scar. The mean time to achieve a flat scar was 20 months. Retina was reattached in all patients except one with 9 months of follow-up. Visual acuity was improved or stabilized in 37 patients (86%) and final median visual acuity was 20/25. No patient presented radiation maculopathy or papillopathy. Proton beam therapy with a dose of 20 gray relative biological effectiveness delivered in 8 fractions provides excellent anatomical and functional results and are comparable with those obtained with the same dose delivered in 4 fractions. Longer follow-up is required to determine the long-term radiation sequelae.

Identifiants

pubmed: 29252976
doi: 10.1097/IAE.0000000000002002
doi:

Substances chimiques

Coloring Agents 0
Indocyanine Green IX6J1063HV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

692-699

Auteurs

Amir Mahdjoubi (A)

Departments of Ophtalmology, and.

Rémi Dendale (R)

Radiation Oncology, Institut Curie, Paris, France.

Laurence Desjardins (L)

Departments of Ophtalmology, and.

Stéphanie Lemaitre (S)

Departments of Ophtalmology, and.

Livia Lumbroso-Le Rouic (L)

Departments of Ophtalmology, and.

Farid Goudjil (F)

Radiation Oncology, Institut Curie, Paris, France.

Nathalie Cassoux (N)

Department of Ophtalmology, Institut Curie, Université Paris-Descartes, Paris, France.

Christine Levy-Gabriel (C)

Departments of Ophtalmology, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH